dupilumab
FDA Approves Dupixent for Pediatric Eosinophilic Esophagitis
The FDA approved Dupixent to treat eosinophilic esophagitis in children ages 1 year and older.
JANUARY 26, 2024
More Data Support Dupilumab for Severe EoE
Dupilumab improves eosinophilic esophagitis, with benefits sustained to 52 weeks, according to updated analyses of ...
MARCH 8, 2023
FDA Expands Dupliumab Indication to EoE
Dupliumab is now indicated for the treatment eosinophilic esophagitis in patients 12 years and older weighing more ...
MAY 23, 2022
FDA Approves First Treatment for Chronic Rhinosinusitis With Nasal Polyps
The FDA granted a new indication for Dupixent to treat adults with nasal polyps accompanied by chronic ...
JUNE 27, 2019
Load more